BIOVERATIV INC (NASDAQ:BIVV) Lifted to “Strong-Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of BIOVERATIV INC (NASDAQ:BIVV) from a hold rating to a strong-buy rating in a research note published on Tuesday morning. They currently have $73.00 price objective on the biotechnology company’s stock.
According to Zacks, “Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. “
BIVV has been the subject of a number of other reports. Argus started coverage on shares of BIOVERATIV INC in a report on Friday, March 31st. They set a hold rating and a $51.00 price target for the company. Cowen and Company raised shares of BIOVERATIV INC from a market perform rating to an outperform rating in a report on Monday, July 10th. Jefferies Group LLC reaffirmed a buy rating on shares of BIOVERATIV INC in a report on Friday, June 30th. Stifel Nicolaus raised their price target on shares of BIOVERATIV INC from $54.00 to $57.00 and gave the company a buy rating in a report on Monday, March 27th. Finally, Deutsche Bank AG started coverage on shares of BIOVERATIV INC in a report on Friday, June 23rd. They set a hold rating and a $65.00 price target for the company. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. BIOVERATIV INC currently has a consensus rating of Buy and a consensus price target of $56.77.
BIOVERATIV INC (NASDAQ BIVV) traded up 0.89% during midday trading on Tuesday, hitting $62.53. 1,024,639 shares of the stock traded hands. BIOVERATIV INC has a one year low of $41.88 and a one year high of $64.41. The company’s 50-day moving average is $60.77 and its 200-day moving average is $55.15. The company has a market cap of $6.76 billion and a PE ratio of 15.29.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/bioverativ-inc-nasdaqbivv-lifted-to-strong-buy-at-zacks-investment-research/1461776.html.
In other BIOVERATIV INC news, insider Diantha Duvall sold 818 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the transaction, the insider now directly owns 2,128 shares in the company, valued at approximately $128,680.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Louis J. Paglia acquired 2,000 shares of BIOVERATIV INC stock in a transaction on Friday, May 26th. The shares were bought at an average price of $57.76 per share, for a total transaction of $115,520.00. Following the completion of the purchase, the director now directly owns 3,056 shares in the company, valued at $176,514.56. The disclosure for this purchase can be found here. Insiders have acquired a total of 94,000 shares of company stock worth $5,256,940 over the last quarter.
About BIOVERATIV INC
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with Analyst Ratings Network's FREE daily email newsletter.